Consensus Amgen Inc. Buenos Aires S.E.

Stocks

AMGN

ARDEUT110665

Pharmaceuticals

End-of-day quote Buenos Aires S.E. 25/08/2026			5-day change	1st Jan Change
23,570.00 ^ARS	-0.51%		+5.18%	+41.39%

12:30pm	AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients	MT
11:36am	AstraZeneca and Amgen announce positive Tezspire trial results in EoE	AN

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

25878e3c6ffb8bc.zlP8lynOyLD-Tzyft61ARYxMX5Z69xm32TPIHoVC7ko.hQuU21P7i_S5f0TV3fk1H_5-aOAlm0HarWu_f851rAuPGqPRYpmS5cl_BA~96d0f01225c46e9fa45fb1c3451abf66

Analysts' recommendations: Amgen Inc.

08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
08-05	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
08-05	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT
08-05	BMO Capital Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
08-05	Scotiabank Adjusts Price Target on Amgen to $450 From $385, Maintains Sector Outperform Rating	MT
08-05	Canaccord Genuity Adjusts Price Target on Amgen to $384 From $366, Maintains Hold Rating	MT
08-05	Baird Adjusts Price Target on Amgen to $230 From $215, Maintains Underperform Rating	MT
08-05	Oppenheimer Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
08-05	BofA Adjusts Price Target on Amgen to $317 From $312	MT
08-05	RBC Capital Adjusts Price Target on Amgen to $400 From $370, Maintains Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+10.56%
	JOHNSON & JOHNSON					+0.93%
	ABBVIE INC.					+5.21%
	ROCHE HOLDING AG					+0.54%
	NOVARTIS AG					-2.25%
	ASTRAZENECA PLC					+27.85%
	AMGEN INC.					-11.78%
	NOVO NORDISK A/S					+1.92%
	GILEAD SCIENCES, INC.					+6.29%
	Average					+4.36%
	Weighted average by Cap.					+5.28%